A comprehensive systematic review of prognostic factors, survival outcomes, and the role of targeted therapies in endometrial cancer.

IF 1.7 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Irish Journal of Medical Science Pub Date : 2025-06-21 DOI:10.1007/s11845-025-03984-7

Ali Raza, Rimsha Abaidullah, Fahad M Alshabrmi, Israr Fatima

{"title":"A comprehensive systematic review of prognostic factors, survival outcomes, and the role of targeted therapies in endometrial cancer.","authors":"Ali Raza, Rimsha Abaidullah, Fahad M Alshabrmi, Israr Fatima","doi":"10.1007/s11845-025-03984-7","DOIUrl":null,"url":null,"abstract":"Study background and objectives: Endometrial cancer, ranking as the 6th most prevalent cancer affecting women globally, is characterized by high mortality rates, recurrence, and poor prognosis. The disease lacks comprehensive understanding and effective treatment options. This meta-analysis focuses on randomized controlled trials to investigate targeted therapies, survival outcomes, and prognostic factors in endometrial cancer.Methods: The study follows the PICOS protocol and PRISMA guidelines, utilizing Review Manager Software (Version 5.4) for meta-analyses. Predetermined outcomes relevant to the topic guide the study search, with the GRADE tool assessing the quality of evidence and Begg's formula and Kendall's Tau evaluating certainty.Results: Results reveal oral anastrozole and vistusertib's efficacy, reducing progression-free survival (PFS) and enhancing protein detection. The meta-analysis indicates that targeted therapies do not significantly improve PFS but reduce adverse effects. Chemotherapy does not considerably improve survival rates, and interventions show no significant difference in prognostic factors.Conclusion: In conclusion, anastrozole and vistusertib emerge as effective targeted therapies for endometrial cancer, supported by clinical trial evidence demonstrating reduced PFS and improved protein detection. Additionally, the carboplatin-paclitaxel combination and radiotherapy in monotherapy show promising clinical outcomes. These findings contribute to a comprehensive understanding of prognostic factors, targeted therapies, and survival outcomes in endometrial cancer, emphasizing the need for further research and clinical trials for optimal disease management.","PeriodicalId":14507,"journal":{"name":"Irish Journal of Medical Science","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Irish Journal of Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11845-025-03984-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Study background and objectives: Endometrial cancer, ranking as the 6th most prevalent cancer affecting women globally, is characterized by high mortality rates, recurrence, and poor prognosis. The disease lacks comprehensive understanding and effective treatment options. This meta-analysis focuses on randomized controlled trials to investigate targeted therapies, survival outcomes, and prognostic factors in endometrial cancer.

Methods: The study follows the PICOS protocol and PRISMA guidelines, utilizing Review Manager Software (Version 5.4) for meta-analyses. Predetermined outcomes relevant to the topic guide the study search, with the GRADE tool assessing the quality of evidence and Begg's formula and Kendall's Tau evaluating certainty.

Results: Results reveal oral anastrozole and vistusertib's efficacy, reducing progression-free survival (PFS) and enhancing protein detection. The meta-analysis indicates that targeted therapies do not significantly improve PFS but reduce adverse effects. Chemotherapy does not considerably improve survival rates, and interventions show no significant difference in prognostic factors.

Conclusion: In conclusion, anastrozole and vistusertib emerge as effective targeted therapies for endometrial cancer, supported by clinical trial evidence demonstrating reduced PFS and improved protein detection. Additionally, the carboplatin-paclitaxel combination and radiotherapy in monotherapy show promising clinical outcomes. These findings contribute to a comprehensive understanding of prognostic factors, targeted therapies, and survival outcomes in endometrial cancer, emphasizing the need for further research and clinical trials for optimal disease management.

查看原文本刊更多论文

对子宫内膜癌的预后因素、生存结果和靶向治疗的作用进行了全面系统的回顾。

研究背景与目的：子宫内膜癌是全球第六大女性常见癌症，具有死亡率高、复发率高、预后差的特点。这种疾病缺乏全面的认识和有效的治疗方案。本荟萃分析侧重于随机对照试验，以研究子宫内膜癌的靶向治疗、生存结果和预后因素。方法：本研究遵循PICOS协议和PRISMA指南，使用Review Manager软件（Version 5.4）进行meta分析。与主题相关的预定结果指导研究搜索，使用GRADE工具评估证据质量，Begg公式和Kendall Tau评估确定性。结果：口服阿那曲唑和vistusertib可降低无进展生存期（PFS），提高蛋白检测。荟萃分析表明，靶向治疗不能显著改善PFS，但能减少不良反应。化疗不能显著提高生存率，干预措施在预后因素方面没有显著差异。结论：综上所述，阿那曲唑和vistusertib是治疗子宫内膜癌的有效靶向药物，临床试验证据表明PFS降低，蛋白检测水平提高。此外，卡铂-紫杉醇联合放疗在单药治疗中显示出良好的临床结果。这些发现有助于全面了解子宫内膜癌的预后因素、靶向治疗和生存结果，强调需要进一步研究和临床试验以获得最佳疾病管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Irish Journal of Medical Science 医学-医学：内科

CiteScore

3.70

自引率

4.80%

发文量

357

审稿时长

4-8 weeks

期刊介绍： The Irish Journal of Medical Science is the official organ of the Royal Academy of Medicine in Ireland. Established in 1832, this quarterly journal is a contribution to medical science and an ideal forum for the younger medical/scientific professional to enter world literature and an ideal launching platform now, as in the past, for many a young research worker. The primary role of both the Academy and IJMS is that of providing a forum for the exchange of scientific information and to promote academic discussion, so essential to scientific progress.